Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegLira vs IDeg in Basal Insulin-Treated Type 2 Diabetes
NCT01392573Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2011
- Primary completion
- Oct 2012
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change From Baseline in HbA1c at 26 weeks. Started Nov 2011; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01392573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01392573.